Business Wire: ReAlta Life Sciences’ RLS-0071 Demonstrates Excellent Safety Profile and Confirmed Target Engagement in First-in-Human Phase 1 Clinical Trial
NORFOLK, Va.--(BUSINESS WIRE)--ReAlta Life Sciences (“ReAlta”), Inc., a clinical stage, rare disease company addressing life-threatening diseases through harnessing the power of the immune system, ...
ReAlta Life Sciences’ RLS-0071 Demonstrates Excellent Safety Profile and Confirmed Target Engagement in First-in-Human Phase 1 Clinical Trial